TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02959411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan is a selective vasopressin receptor antagonist that inhibits activation of the V2 receptor and synthesis and insertion of the aquaporin2 channel into the apical membrane of the renal collecting duct. Tolvaptan inhibits the reabsorption of free water, inducing free water diuresis and increasing serum sodium levels without adversely influencing electrolyte levels or stimulating the sympathetic nervous system or renin-angiotensin system.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care diuretic therapy
Description: Usual standard of care diuretic therapy for patients hospitalized with acute decompensated heart failure
Study: NCT02684032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib weekly intravenous starting at 180 mg/week in a 4 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib weekly intravenous starting at 180 mg/week in a 4 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib weekly intravenous starting at 180 mg/week in a 4 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib weekly intravenous starting at 180 mg/week in a 4 week cycle.
Study: NCT04068792

Intervention type: OTHER
Group type: OTHER
Intervention: RSV Mobile Application
Description: Participants will not receive any intervention in observational phase of this study. Participant's respiratory symptoms will be captured by RSV mobile application installed in participant's caregiver/parent mobile phone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants in each Age Group (1,2,3) will receive matching placebo (volume placebo to match the calculated volume of the JNJ-53718678 dose) orally twice daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 2.5 mg/kg
Description: JNJ-53718678 will be administered to Age Group 1 twice daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 3 mg/kg
Description: JNJ-53718678 will be administered to Age Group 2 twice daily for 7 days.
Study: NCT02684032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib weekly intravenous starting at 180 mg/week in a 4 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib initiated at 125 mg daily: 3 out of 4 weeks in a 4 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib initiated at 125 mg daily: 3 out of 4 weeks in a 4 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib initiated at 125 mg daily: 3 out of 4 weeks in a 4 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib initiated at 125 mg daily: 3 out of 4 weeks in a 4 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib initiated at 125 mg daily: 3 out of 4 weeks in a 4 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole at 2.5 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole at 2.5 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant administered intramuscularly at 500 mg on Day 1, 15 and 28 and then every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant administered intramuscularly at 500 mg on Day 1, 15 and 28 and then every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant administered intramuscularly at 500 mg on Day 1, 15 and 28 and then every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant administered intramuscularly at 500 mg on Day 1, 15 and 28 and then every 28 days.
Study: NCT02067689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Application of a weak electrical current to the scalp

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Application of a weak electrical current to the scalp

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Application of a weak electrical current to the scalp

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Application of a weak electrical current to the scalp

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Application of a weak electrical current to the scalp
Study: NCT04068792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 4.5 mg/kg
Description: JNJ-53718678 will be administered to Age Group 3 twice daily for 7 days.
Study: NCT02067689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Application of a weak electrical current to the scalp
Study: NCT01029704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGT0001442
Description: Segment 1 is a single center, open labeled, ascending dose study in diabetic subjects who will receive 5, 10, 20, or 50 mg of EGT0001442 capsules orally once daily for 28 days.~Segment 2 is a multi-center, double-blind, placebo-controlled parallel group study. Diabetic subjects will be randomly assigned to receive oral EGT0001442 at 5, 10, 20, or 50 mg/day for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules to match EGT0001442
Description: Segment 1: Not applicable.~Segment 2: Diabetic subjects will be randomly assigned to receive oral placebo once daily for 28 days.
Study: NCT04440540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietitian led life style modification intervention
Description: lifestyle changes supervised by dietitians

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional care (control)
Description: receive routine care
Study: NCT00840931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Patients will take 10 mg capsules of lenalidomide per day for 21 days followed by 7 days of rest. This 28 day period is considered 1 cycle. Patients will receive 4 treatment cycles with 28 days in each cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bystander vaccine
Description: In addition to lenalidomide, during each 28 day cycle patients will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8 immunizations during the 4 cycle treatment period.
Study: NCT03294343

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: salpingo-oophorectomy only by laparoscopy
Description: Salpingo-oophorectomy are provided for carriers with mutation genes of BRCA1, BRCA2 (both belonging to mutation genes of hereditary breast and ovarian cancer syndrome, HBOCS) and ATM, BRIP1, RAD51, RAD51C, and RAD51D (all belonging to mutation genes of other hereditary ovarian cancer syndrome). Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: salpingo-oophorectomy with hysterectomy by laparoscopy
Description: Salpingo-oophorectomy with hysterectomy are provided for carriers with mutation genes of MLH1, MSH2, MSH6, PMS2, EPCAM (all belonging to mutation genes of Lynch syndromes) and STK11. Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.
Study: NCT03183804

Intervention type: BIOLOGICAL
Intervention: ALLO-ASC-DFU
Description: Application of ALLO-ASC-DFU sheet to diabetic foot ulcer. This study is a follow-up study without intervention.

Intervention type: OTHER
Intervention: Standard therapy
Description: Standard therapy conducted for patients with diabetic foot ulcer. This study is a follow-up study without intervention.
Study: NCT04775732

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: infliximab therapeutic drug monitoring
Description: dose optimization of infliximab based on a predefined dosing algorithm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab therapeutic drug monitoring
Description: dose optimization of infliximab based on a predefined dosing algorithm
Study: NCT00774592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOYC
Description: FOYC is a face-to-face, eight-session, group behavioral intervention based on protection motivation theory and emphasizing skills and decision-making.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOYC
Description: FOYC is a face-to-face, eight-session, group behavioral intervention based on protection motivation theory and emphasizing skills and decision-making.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal for it (GFI)
Description: GFI is a one-session parent intervention consisting of a 20-minute video followed by a discussion regarding the process of setting and reaching goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wonderous Wetlands
Description: Wonderous Wetlands is an eight-session, group intervention for youth. It includes field projects and discussions based on ways to save our environment.
Study: NCT01688908

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Screening
Description: 1. Upper G.I. endoscopic examination with Lugols Iodine in esophagus~2. Biopsy at the visually abnormal sites~3. Pathologic examination of all biopsy tissue specimens~4. Subsequent re-examination and further medical services among individuals who already have high-grade lesions found at screening.~5. Advises of endoscopic or surgical treatment will be given to participants who are diagnosed of high grade upper G.I. lesions.
Study: NCT02725190

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleepless night
Description: Each subject will undergo 28 hours of sleep deprivation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Normal sleep night
Description: Normal sleep at home before trial.
Study: NCT03463668

Intervention type: DEVICE
Intervention: uncovered metal duodenal prosthesis
Description: Implantation of an uncovered metal duodenal prosthesis for symptomatic tumor stenosis
Study: NCT03699137

Intervention type: OTHER
Intervention: No interventions
Description: No interventions

Intervention type: OTHER
Intervention: No interventions
Description: No interventions
Study: NCT04738630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008
Description: 200 mg administered as IV infusion on Day 1 of each 21-day cycle.
Study: NCT02560298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00647660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg
Description: 80/5mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corzide® Tablets 80 mg/5 mg
Description: 80/5mg, single dose fasting
Study: NCT01497613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRISM C: Computer Condition
Description: A specialized computer system designed to support social connectivity and access to resources; knowledge and prospective memory

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PRISM B: Notebook Condition
Description: Telephone check-in calls and a notebook that contains information about community resources, games; topics of interests to seniors; a calendar and contact list.
Study: NCT01065402

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PPB-R-203-Based Meal
Description: PPB-R-203 is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203 is resistant starch (RS). Resistant starch can be regarded as a component of dietary fiber. Some forms of RS are present naturally in many foods, and average global consumption is estimated at 3-10 g/day. PPB-R-203-Based is the diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: TK9-Based Meal
Description: TK9, Taikeng 9, is one commercially available rice manufacture by Yeedon Enterprise Co., Ltd. TK9-Based Meal is a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
Study: NCT00551512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP501 and Cisplatin
Description: CBP501 is given IV on Day 1 of each cycle (every 21 days). Dose escalation of CBP501 and cisplatin will be starting doses of 3.6 mg/m² CBP501 and 50 mg/m² cisplatin (Dose Level 1). Step 1, if during the first 2 cycles, at least 2 out of 3 to 6 patients experience Dose Limiting Toxicity (DLT) at 50 mg/m² cisplatin, then the cisplatin dose will be de-escalated to 30 mg/m². If no more than 1 out of 6 patients experiences DLT, cisplatin dose will be escalated to 75 mg/m². Step 2, dose escalation will be performed using the cisplatin MTD, with escalating CBP501 doses. CBP501 dose escalation will take place until the MTD has been defined or 74 mg/m² is reached.
Study: NCT01428154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: A single 1.5 μg/kg subcutaneous (SC) dose administration on day 1
Study: NCT03456505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation Training
Description: A researcher will guide participants through 5 mindfulness meditations, each lasting 11 minutes in length.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Listening
Description: A researcher will read participants 5 selections from The Natural History of Selborne, each lasting 11 minutes in length.
Study: NCT02348112

Intervention type: DEVICE
Intervention: Altis Single Incision Sling
Description: Altis is a minimally invasive, adjustable incontinence sling that is placed through a single incision in the vaginal wall and anchored inside the body. The sling has an integrated tensioning system eliminating the need for additional skin exits.
Study: NCT04192877

Intervention type: DIAGNOSTIC_TEST
Intervention: Vagus Nerve Neurodynamic test
Description: The VN-NDT has been developed starting from the VN morphology selecting the physiological movements that induce the greater mechanical tension on the nerve. The subjects will be assessed supine on an examination table with assessors standing at the cranial short side of the table. Upper cervical flexion and contralateral lateral flexion had been selected for loading the intracranial portion. The ipsilateral neck rotation had been selected for loading the cervical tract. Keeping the subject's head in the final movements combination gentle movements of the upper abdomen caudally and cranially had been selected for loading the thoracic tract and used as discrimination maneuver. The test will be declared positive (indicating abnormal responses) if symptoms will be felt in anatomical regions other than the neck on the same side of the test and discrimination maneuvers changed the subject's symptoms indicating a neurogenic source, otherwise it will be declared negative.
Study: NCT02979847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hybrid approach
Description: Before transseptal puncture, epicardial puncture is performed through subxyphoid approach. Atrial epicardial potentials are recorded using multi-electrode catheter, leading an activation map for atrial tachycardia and map for continuous fractionated atrial electrograms during atrial fibrillation. Endocardial potentials are also recorded in the same fashion. Procedural endpoint is a tachycardia termination or a noninducibility of tachycardia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional endocardial approach
Description: Atrial endocardial potentials are recorded using multi-electrode catheter, leading an activation map for atrial tachycardia and map for continuous fractionated atrial electrograms during atrial fibrillation. Procedural endpoint is a tachycardia termination or a noninducibility of tachycardia.
Study: NCT02803151

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy
Description: SABR with 36 to 45 Gy in six fractions to the defined target volume with met organ-at-risk constraint criteria using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc). Treatment should be given once per day, 2-3 fractions per week with no more than 2 consecutive daily fractions, over 2 to 2.5 weeks.
Study: NCT02855437

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IVR (Phone call)
Description: IVR will auto dial participants at a schedule time. Participants complete questions using their phone keypad. Participants can also call the IVR to complete surveys if they experience a flare. The IVR will be programmed to call the patient weekly for 26 weeks to complete a weekly Gout Flare Survey and Patient Reported Outcomes Survey. Consistent with the published gout flare self-report definition, gout flare ascertainment questions will include whether the recent flare is similar to past flares, the number of swollen joints and the number of warm joints. Pain at rest during the attack will be assessed on a 0-9 scale. Further questions will include peak pain, timing of attack and duration of attack if completed. We will capture patient reported outcome measures (e.g. pain, fatigue, sleep) using instruments from NIH PROMIS. Following completion of 26 week IVR period participants will crossover to RheumPro arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RheumPro (Smartphone application)
Description: RheumPRO will be programmed to notify participants weekly for 26 weeks via a scheduled pop-up to complete Gout Flare and Patient Reported Outcomes Surveys. Participants self-navigate through the survey questions using their smartphone. If participants do not complete the Gout Flare or Patient Reported Outcomes surveys RheumPro will generate 2 more pop-ups at the same time over the proceeding 2 days (eg. Tuesday 4 PM, Wednesday 4 PM). Participants can also open the RheumPro application on their smartphone and complete surveys or if they experience a flare on a day they are not scheduled to complete a survey. Following completion of 26 week RheumPro period participants will crossover to IVR arm.
Study: NCT04878523

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multi berries juice
Description: Testing product
Study: NCT00787215

Intervention type: OTHER
Intervention: observational: no treatment involved
Description: observational: no treatment involved
Study: NCT01264770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib and placebo injections
Description: Fostamatinib 100mg twice daily and placebo injection once every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib and placebo injections
Description: Fostamatinib 100mg twice daily / fostamatinib 150mg once daily and placebo injection once every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib and placebo injections
Description: Fostamatinib 100mg twice daily / fostamatinib 100mg once daily and placebo injection once every two weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab and placebo of fostamatinib
Description: Adalimumab 40mg injection once every two weeks and placebo to fostamatinib twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of fostamatinib, fostamatinib, and placebo injections
Description: Placebo injection once every two weeks. Placebo to fostamatinib for six weeks, followed by fostamatinib 100mg twice daily (Group F) / fostamatinib 100mg twice daily then 150mg once daily (Group G).
Study: NCT03570346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: Subjects will be randomized into 3 dose groups orally twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized into 3 dose groups orally twice daily.
Study: NCT02976103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jacki Recovery jacket
Description: An outer jacket that holds surgical drains and allows access for blood draws

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care Pain medicine/management
Description: Standard care pain medicine and management in hospitals where the study enrolls

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care Pain medicine/management
Description: Standard care pain medicine and management in hospitals where the study enrolls
Study: NCT01985360

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Catheterization
Description: Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
Study: NCT04878523

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Blank
Study: NCT04267133

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Facial video of detection of cardiac disease
Description: This project proposes to evaluate a non-contact video recording technology to detect the presence of AF. The technology extracts a pulsatile signal by measuring the subtle variations in skin color of a patient's face (flushing) due to the variations of blood volume underneath the skin. The technology uses a standard web camera. This technique is videoplethysmography (VPG).